Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 47: 1345-1346, 2001;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (3)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Price, C. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Price, C. P.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2001;47:1345-1346.)
© 2001 American Association for Clinical Chemistry, Inc.

Editorial

Microarrays: The Reincarnation of Multiplexing in Laboratory Medicine, But Now More Relevant?

Christopher P. Price1

1 Department of Clinical Biochemistry St. Bartholomew’s and the Royal London School of Medicine and Dentistry Turner Street London E1 2AD, United Kingdom Fax 44-20-7377-1544 E-mail c.p.price@mds.qmw.ac.uk

Multiplexing is a relatively new addition to the Oxford English Dictionary and in the encyclopedic version is defined as "the simultaneous transmission of several messages along a single channel of communication". It is also a relatively new addition to the vocabulary of the clinical chemist, having been imported from the lexicon of the genomics, proteomics, and drug discovery scientists, but it is not a new concept for the clinical chemist who has been exposed to the use of so-called multichannel analyzers for many years, first continuous flow and then discrete analyzers. Some historians of automation might look back to the centrifugal analyzer as the first challenge to multichannel analysis, but there is now at least one example of this technology that provides a profile of analytes on a single sample (1). If these are indeed early examples of multiplexing analyzers, then they distinguish themselves—by today’s standards—by using large amounts of sample and reagents, by a choice of analytes that are not always clinically justified, and by an inability (with a few notable exceptions) to embrace immunoassay and other ligand-binding assay techniques for low-concentration analytes. However, the greatest legacy of the first era of multiplexing analysis is probably the perception that there is too much laboratory testing as well as numerous apocryphal stories of patients being investigated after the generation of an abnormal result, rather than for the presenting symptoms!

So with the advent of microarray platforms, are we seeing the reincarnation of multiplexing analytical strategies and the evolutionary cycle turning full circle? The concept of the multianalyte array based on immunologic capture and interrogation technology is not new, with an editorial on the subject in this Journal almost a decade ago (2). So what has been achieved in the intervening period? Certainly the interrogation of captured . . . [Full Text of this Article]


References




The following articles in journals at HighWire Press have cited this article:


Home page
 LupusHome page
S. Binder
Autoantibody Detection Using Multiplex Technologies
Lupus, July 1, 2006; 15(7): 412 - 421.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the American Association for Clinical Chemistry.